#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Short-bowel syndrome Lennox-Gastaut syndrome Lip and/or oral cavity cancer Scleroderma associated digital ulcer Ventricular fibrillation Angelman's syndrome Anaemia Hepatitis D Cortical dysplasia Brain injury Polycythaemia vera Orthostatic hypotension Glomerulonephritis minimal lesion Mitochondrial myopathy Pulmonary fibrosis More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma – Basic Information IgA nephropathy – Diagnostics Malignant fibrous histiocytoma – Life with Disease Haemolytic uraemic syndrome Von Willebrand’s disease Cerebral arteriovenous malformation haemorrhagic Noonan syndrome – Basic Information Krabbe’s disease Waldenstrom’s macroglobulinaemia recurrent Mucopolysaccharidosis II – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    GSK5764227 Motixafortide Histamine Hydrochloride ANUMIGILIMAB Thiamine Hydrochloride AMG 732 Sparsentan GEN1078 Other Blood Products L-LEUCINE Mva-209-Fsp-B4 Allopurinol Fexofenadine MZE829 [18F]CPFPX For-6219 Apremilast Zanidatamab Cyclophosphamide Elexacaftor More therapies…

    Learn about Your Condition

    Haemorrhage Implantation complication Colon cancer stage IV Prinzmetal angina Pancreatic carcinoma recurrent Lichen planopilaris Cervix carcinoma stage III Hypochromic anaemia Hyperlipidaemia Partial seizures Psychological trauma Burning mouth syndrome Post procedural swelling Renal cancer metastatic Dupuytren's contracture More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer stage IIIA

  • Study on Thoracic Radiotherapy and Durvalumab for Elderly or Frail Stage III Non-Small Cell Lung Cancer Patients Unable to Undergo Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer stage IIIA
    • Non-small cell lung cancer stage IIIB
    Investigated Drugs:
    • Durvalumab
    Germany

  • Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage II
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer stage IIIA
    Investigated Drugs:
    • Ociperlimab
    • Tislelizumab
    • Pembrolizumab
    France Germany Italy The Netherlands Poland Spain

  • Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenosquamous cell lung cancer recurrent
    • Adenosquamous cell lung cancer stage III
    • Adenosquamous cell lung cancer stage IV
    Investigated Drugs:
    • Atl001
    • Pembrolizumab
    France Germany Spain

  • Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage I
    • Non-small cell lung cancer stage II
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • Osimertinib
    Belgium France Germany Italy Poland Spain +1

  • Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Incb099280
    Greece Hungary Romania
Previous Page
1 2 3

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!